Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29659573 | 1.00 | YTHDC1 (0.55) | YTHDC1ADORA3ADORA2AADORA1NPC1 | |
| SCHEMBL30410412 | 0.90 | ADORA3 (0.49) | ADORA3ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL29659686 | 0.89 | ADORA3 (0.48) | ADORA3ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL20547422 | 0.89 | ADORA3 (0.48) | ADORA3ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL2002143 | 0.88 | NPC1 (0.64) | ADORA3ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30410491 | 0.88 | NPC1 (0.52) | YTHDC1ADORA3ADORA2AADORA1NPC1 | |
| SCHEMBL20547622 | 0.86 | CCNE2 (0.63) | YTHDC1ADORA3ADORA2AADORA1NPC1 | |
| SCHEMBL30410761 | 0.85 | ADORA3 (0.51) | ADORA3ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL20547488 | 0.85 | YTHDC1 (0.60) | YTHDC1ADORA3ADORA2AADORA1NPC1 | |
| SCHEMBL20547189 | 0.84 | ADORA3 (0.57) | YTHDC1ADORA3ADORA2AADORA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643413-B2 | 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2023-05-09 | — | — | US | disclosed |
| EP-3615535-B1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIV PALACKEHO (CZ) | 2022-06-15 | — | — | EP | disclosed |
| US-20200157105-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-05-21 | — | — | US | disclosed |
| EP-3615535-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | Univerzita Palackého v Olomouci (CZ) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018196893-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157105-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | ADORA2A, UNG, P2RY6 | YTHDC1 1391/4885ADORA3 9/4885ADORA2A 1/4885 |
| US-11643413-B2 | 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders | ADORA2A, UNG, P2RY6 | YTHDC1 1391/4885ADORA3 9/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.